| [1] |
Amini N, Ejaz A, Spolverato G, et al. Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis[J]. J Surg Oncol, 2014, 110(2):163-170.
|
| [2] |
Doussot A, Gonen M, Wiggers JK, et al. Recurrence patterns and disease-free survival after resection of intrahepatic cholangiocarcinoma: preoperative and postoperative prognostic models[J]. J Am Coll Surg, 2016, 223(3):493-505, e2.
|
| [3] |
Tomimaru Y, Eguchi H, Wada H, et al. Liver resection combined with inferior vena cava resection and reconstruction using artificial vascular graft: a literature review[J]. Ann Gastroenterol Surg, 2018, 2(3):182-186.
|
| [4] |
Harada N, Yoshizumi T, Yamashita YI, et al. Impact and prediction of lymph node involvement in patients with intrahepatic cholangiocarcinoma after curative resection[J]. Anticancer Res, 2017, 37(7):3763-3769.
|
| [5] |
Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? a meta-analysis of risk factors for intrahepatic cholangiocarcinoma[J]. J Hepatol, 2012, 57(1):69-76.
|
| [6] |
Zhang XF, Lv Y, Weiss M, et al. Should utilization of lymphadenectomy vary according to morphologic subtype of intrahepatic cholangiocarcinoma?[J]. Ann Surg Oncol, 2019, 26(7): 2242-2250.
|
| [7] |
Sahara K, Tsilimigras DI, Merath K, et al. Therapeutic index associated with lymphadenectomy among patients with intrahepatic cholangiocarcinoma: which patients benefit the most from nodal evaluation?[J]. Ann Surg Oncol, 2019, 26(9):2959-2968.
|
| [8] |
Kim DH, Choi DW, Choi SH, et al. Is there a role for systematic hepatic pedicle lymphadenectomy in intrahepatic cholangiocarcinoma? a review of 17 years of experience in a tertiary institution[J]. Surgery, 2015, 157(4):666-675.
|
| [9] |
Najafi M, Farhood B, Mortezaee K. Contribution of regulatory T cells to cancer: a review[J]. J Cell Physiol, 2019, 234(6):7983-7993.
|
| [10] |
Ciria R, Cherqui D, Geller DA, et al. Comparative short-term benefits of laparoscopic liver resection: 9 000 cases and climbing[J]. Ann Surg, 2016, 263(4):761-777.
|
| [11] |
Ratti F, Cipriani F, Ariotti R, et al. Safety and feasibility of laparoscopic liver resection with associated lymphadenectomy for intrahepatic cholangiocarcinoma: a propensity score-based case-matched analysis from a single institution[J]. Surg Endosc, 2016, 30(5):1999-2010.
|
| [12] |
Lee W, Park JH, Kim JY, et al. Comparison of perioperative and oncologic outcomes between open and laparoscopic liver resection for intrahepatic cholangiocarcinoma[J]. Surg Endosc, 2016, 30(11):4835-4840.
|
| [13] |
Khan S, Beard RE, Kingham PT, et al. Long-term oncologic outcomes following robotic liver resections for primary hepatobiliary malignancies: a multicenter study[J]. Ann Surg Oncol, 2018, 25(9): 2652-2660.
|
| [14] |
Weber SM, Ribero D, O'Reilly EM, et al. Intrahepatic cholangiocarcinoma: expert consensus statement[J]. HPB, 2015, 17(8):669-680.
|
| [15] |
Hyder O, Marques H, Pulitano C, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience[J]. JAMA Surg, 2014, 149(5):432-438.
|
| [16] |
Mavros MN, Economopoulos KP, Alexiou VG, et al. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis[J]. JAMA Surg, 2014, 149(6): 565-574.
|
| [17] |
Spolverato G, Kim Y, Alexandrescu S, et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection[J]. Ann Surg Oncol, 2016, 23(1):235-243.
|
| [18] |
Becker NS, Rodriguez JA, Barshes NR, et al. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period[J]. J Gastrointest Surg, 2008, 12(1):117-122.
|
| [19] |
Vilchez V, Shah MB, Daily MF, et al. Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database[J]. HPB, 2016, 18(1):29-34.
|
| [20] |
Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment[J]. Hepatology, 2016, 64(4):1178-1188.
|
| [21] |
Scheuermann U, Kaths JM, Heise M, et al. Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience[J]. Eur J Surg Oncol, 2013, 39(6):593-600.
|
| [22] |
Wu ZF, Zhang HB, Yang N, et al. Postoperative adjuvant transcatheter arterial chemoembolisation improves survival of intrahepatic cholangiocarcinoma patients with poor prognostic factors: results of a large monocentric series[J]. Eur J Surg Oncol, 2012, 38(7):602-610.
|
| [23] |
Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma[J]. J Surg Oncol, 2015, 111(2):213-220.
|
| [24] |
Konstantinidis IT, Koerkamp BG, Do RK, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone[J]. Cancer, 2016, 122(5):758-765.
|
| [25] |
Shinohara ET, Mitra N, Guo M, et al. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2008, 72(5):1495-1501.
|
| [26] |
Hammad AY, Berger NG, Eastwood D, et al. Is radiotherapy warranted following intrahepatic cholangiocarcinoma resection? the impact of surgical margins and lymph node status on survival[J]. Ann Surg Oncol, 2016, 23(Suppl 5):912-920.
|
| [27] |
Mahadevan A, Dagoglu N, Mancias J, et al. Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma[J]. J Cancer, 2015, 6(11):1099-1104.
|
| [28] |
Kim JH, Won HJ, Shin YM, et al. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma[J]. AJR Am J Roentgenol, 2011, 196(2):W205-209.
|
| [29] |
Han K, Ko HK, Kim KW, et al. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis[J]. J Vasc Interv Radiol, 2015, 26(7):943-948.
|
| [30] |
Kato A, Shimizu H, Ohtsuka M, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study[J]. Ann Surg Oncol, 2013, 20(1):318-324.
|
| [31] |
Le Roy B, Gelli M, Pittau G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Br J Surg, 2018, 105(7):839-847.
|
| [32] |
Sumiyoshi T, Shima Y, Okabayashi T, et al. Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma[J]. World J Surg, 2018, 42(9):2910-2918.
|
| [33] |
Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase Ⅲ study[J]. J Clin Oncol, 2019, 37(8):658-667.
|
| [34] |
Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019, 20(5):663-673.
|
| [35] |
Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma-evolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol, 2018, 15(2):95-111.
|
| [36] |
Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015, 47(9):1003-1010.
|
| [37] |
Javle M, Lowery M, Shroff RT, et al. Phase Ⅱ study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma[J]. J Clin Oncol, 2018, 36(3):276-282.
|
| [38] |
Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma[J]. Br J Cancer, 2019, 120(2):165-171.
|
| [39] |
Lowery MA, Burris HA, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma:a phase 1 study[J]. Lancet Gastroenterol Hepatol, 2019, 4(9):711-720.
|
| [40] |
Lamberti D, Cristinziano G, Porru M, et al. HSP90 inhibition drives degradation of FGFR2 fusion proteins: implications for treatment of cholangiocarcinoma[J]. Hepatology, 2019, 69(1):131-142.
|